Podcasts about gastric cancer

In this video we cover Gastric Cancer / Stomach Cancer, looking at risk factors for it as well as what are the signs and symptoms of Gastric Cancer (with Troisier's sign!). Also includes the most common locations of gastric cancer, how gastric cancer is diagnosed (including staging), and how is gastric cancer treated. PDFs available at: https://rhesusmedicine.com/pages/gastroenterologyFor more medicine videos consider subscribing (if you found any of the info useful!): https://www.youtube.com/channel/UCRks8wB6vgz0E7buP0L_5RQ?sub_confirmation=1Buy Us A Coffee!: https://www.buymeacoffee.com/rhesusmedicineVideo Timestamps:0:00 How common is Gastric Cancer0:10 Risk Factors for Gastric Cancer1:07 Where is Gastric Cancer most common? 1:19 Types of Gastric Cancer1:35 Most Common Site of Gastric Cancer (Which part of the stomach is most commonly affected)1:49 Signs and Symptoms of Gastric Cancer (Gastric Cancer Symptoms) 2:39 What is Troisier's Sign? (Virchows Node)2:51 Gastric Cancer Diagnosis3:10 Gastric Cancer Staging4:03 Gastric Cancer Prognosis4:35 Gastric Cancer TreatmentLINK TO SOCIAL MEDIA: https://www.instagram.com/rhesusmedicine/ReferencesWorld Journal of Gastroenterology, 2008. Role of symptoms in diagnosis and outcome of gastric cancer. World Journal of Gastroenterology, 14(8), pp.1149–1155. [online] Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2690660/. PMCMachlowska, J., Baj, J., Sitarz, M., Maciejewski, R. & Sitarz, R., 2020. Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies. International Journal of Molecular Sciences, 21(11):4012. [online] Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312039/. PubMedWikipedia, 2025. Stomach carcinoma / Gastric cancer. [online] Available at: https://en.wikipedia.org/wiki/Stomach_carcinoma.ScienceDirect Topics, 2025. Stomach carcinoma – Medicine and Dentistry. [online] Available at: https://www.sciencedirect.com/topics/medicine-and-dentistry/stomach-carcinoma. ScienceDirectWorld Health Organization (WHO), 2025. Cancer fact sheet. [online] Available at: https://www.who.int/news-room/fact-sheets/detail/cancer.Disclaimer: Please remember this podcast and all content from Rhesus Medicine is for educational and entertainment purposes only and is not a guide to diagnose or to treat any form of condition. The content is not to be used to guide clinical practice and is not medical advice. Please consult a healthcare professional for medical advice.

Claudin 18.2 is a novel biomarker for advanced gastric and gastroesophageal junction cancer. Patients who test positive for claudin 18.2 may be candidates for the monoclonal antibody, zolbetuximab, which directly targets this biomarker. In this episode, CANCER BUZZ speaks with Manish A. Shah, MD, FASCO, director of the Gastrointestinal Oncology Program at Weill Cornell Medicine, about how claudin 18.2 is shaping treatment decisions and some of the clinical trials pursuing more information about the potential for this biomarker. CANCER BUZZ also speaks with Sasha Watson, PharmD, outpatient medical oncology clinical pharmacist at Sylvester Comprehensive Cancer Center, about the importance of engaging the whole multidisciplinary team in biomarker testing for optimal patient outcomes.   "I often talk to my gastroenterologist and ask them to get more than 1 biopsy to make sure that we have enough tissue for now and even in the future." - Manish A. Shah, MD, FASCO Instead of lumping all gastric cancers into one group, we use these biomarkers to split them out... We have more refined and tailored treatments for patients with gastroesophageal adenocarcinoma based on these biomarkers." - Manish A. Shah, MD, FASCO "Nurses in the infusion center are a huge help that we absolutely need, and administering this treatment would be very difficult if we didn't have scaled and experienced nurses here." - Aleksandra (Sasha) Watson, PharmD "What I see is just a lot of patients having hope—some new part of their cancer that we can target with a drug that we previously didn't have any options for." - Aleksandra (Sasha) Watson, PharmD   Guests:               Manish A. Shah, MD, FASCO  Director, Gastrointestinal Oncology Program Weill Cornell Medicine New York, NY Aleksandra (Sasha) Watson, PharmD  Outpatient Medical Oncology Clinical Pharmacist (GI + Sarcoma) Sylvester Comprehensive Cancer Center Miami, FL Resources ACCC Biomarkers Webpage ACCCBuzz Blog: Importance of Biomarker Testing, Patient Goals and Education When Treating Gastric Cancer

In this episode, we review the high-yield topic of⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠Gastric Cancer⁠⁠⁠⁠⁠ from the Oncology section.Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets

Stacy Martin says genetic testing saved her life.   The testing indicated she had the CDH1 mutation.  The mutation gave her an 80 percent chance of getting gastric cancer and a 60 percent chance of breast cancer.  She opted for a prophylactic total gastrectomy to remove her stomach and addressed the possibility of breast cancer with a bilateral mastectomy.  Without a stomach, Stacy has had to change the way she eats, requiring food every two hours, and having to completely chew everything she eats.  Despite this live-changing surgery, Stacy is leading a healthy and happy life.   Unlike most people with cancer, Stacy's diagnosis was not preceded by symptoms.  Her mother had already been diagnosed with Stage IV uterin cancer.  That prompted Stacy and her siblings to undergo a genetic panel test.  It revealed Stacy had the CDH1 mutation, which meant she an 80 percent chance of getting gastric cancer and a 60 percent chance of breast cancer.    She had three options but chose to be proactive with a prophylactic total gastrectomy in 2019, a procedure that removed her stomach.  It was after the surgery that pathology revealed Stacy had gastric cancer in her removed stomach.    After successfully addressing the possibility of stomach cancer, she did the same with breast cancer with a bilateral mastectomy in 2020.   Stacy Martin said the toughest part of her cancer experience wasn't the treatment, but what she dealt with upon its completion.  She said she had to learn how to eat, and that without a stomach, she had to eat every two hours.  While she took snacks with her wherever she went, she had to alternate between snacks and something more substantial, making sure she got enough protein and carbohydrates.  Anything she ate had to be completely chewed because she no longer had the gastric juices in her stomach that break down food.  The only thing she can't eat are raw oysters because she says they are impossible to chew.   Stacy says genetic testing saved her life but admits it is not for everybody because the decision to go forth with such testing is a deeply personal decision because some people don't want to know what the tests could reveal. Despite her cancer journey, Stacy lives a happy life.  She resumed her passion of hiking near her home in Chattanooga, Tennessee, and consumption of nuts resulted in her establishing Seahorse Snacks, which she operates out of her home.   Additional Resources:   Seahorse Snacks: https://www.seahorsesnacks.com   No Stomach For Cancer: https://www.nostomachforcancer.org          

Dr Philip Smith, Digital and Education Editor of Gut and Honorary Consultant Gastroenterologist at the Royal Liverpool Hospital, Liverpool, UK interviews Dr Jyh-Ming Liou from Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan on the paper "Screening and eradication of Helicobacter pylori for gastric cancer prevention: Taipei Global Consensus II" published in paper copy in Gut in November 2025. Please subscribe to the Gut podcast on your favourite platform to get the latest podcast every month. If you enjoy our podcast, you can leave us a review or a comment on Apple Podcasts (https://apple.co/3UOTwqS) or Spotify (https://spoti.fi/3Ifxq9p).

In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Gastric Cancer from the Oncology section at ⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

CME credits: 0.50 Valid until: 30-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/quick-case-strategizing-treatment-selection-in-her2-pd-l1-gastric-cancer/37692/ This activity examines first-line treatment strategies for advanced HER2-negative upper gastrointestinal cancers. Expert commentary highlights the role of biomarker testing, including PD-L1 CPS and CLDN18.2, in guiding therapeutic decisions. Key clinical trial data on anti-PD-1 therapies such as nivolumab, pembrolizumab, and tislelizumab are discussed, along with regimen-specific adverse event profiles. Patient case examples illustrate the application of guideline-based treatment selection utilizing biomarker status in clinical practice.

This week's episode will be focusing on Gastric Adenocarcinoma. We will go over all the important details on risk factors, diagnostic work-up, staging and treatment for both local regional disease and metastatic disease with updates in 2025 since we last covered this topic in 2023.

Dr. Wenqing Li joins Peng Zhang to discuss a recent study integrating genetics and transcriptomics for risk stratification of gastric cancer. The conversation explores the global epidemiology of gastric cancer, its high prevalence and mortality rates, particularly in East Asia and China, and the complex interplay of genetic and environmental risk factors, notably Helicobacter pylori infection.Read the full article:https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(25)00211-7/fulltext?dgcid=buzzsprout_icw_podcast_July_25_ebiomContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EHA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 30, 2026.Hope on the Horizon in Gastric Cancer: Breakthroughs in Personalized Care With Immunotherapy and Targeted Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Hope For Stomach Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Astellas, AstraZeneca, BeOne Medicines, Bristol Myers Squibb, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EHA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 30, 2026.Hope on the Horizon in Gastric Cancer: Breakthroughs in Personalized Care With Immunotherapy and Targeted Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Hope For Stomach Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Astellas, AstraZeneca, BeOne Medicines, Bristol Myers Squibb, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EHA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 30, 2026.Hope on the Horizon in Gastric Cancer: Breakthroughs in Personalized Care With Immunotherapy and Targeted Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Hope For Stomach Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Astellas, AstraZeneca, BeOne Medicines, Bristol Myers Squibb, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EHA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 30, 2026.Hope on the Horizon in Gastric Cancer: Breakthroughs in Personalized Care With Immunotherapy and Targeted Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Hope For Stomach Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Astellas, AstraZeneca, BeOne Medicines, Bristol Myers Squibb, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EHA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 30, 2026.Hope on the Horizon in Gastric Cancer: Breakthroughs in Personalized Care With Immunotherapy and Targeted Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Hope For Stomach Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Astellas, AstraZeneca, BeOne Medicines, Bristol Myers Squibb, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EHA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 30, 2026.Hope on the Horizon in Gastric Cancer: Breakthroughs in Personalized Care With Immunotherapy and Targeted Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Hope For Stomach Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Astellas, AstraZeneca, BeOne Medicines, Bristol Myers Squibb, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EHA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 30, 2026.Hope on the Horizon in Gastric Cancer: Breakthroughs in Personalized Care With Immunotherapy and Targeted Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Hope For Stomach Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Astellas, AstraZeneca, BeOne Medicines, Bristol Myers Squibb, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EHA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 30, 2026.Hope on the Horizon in Gastric Cancer: Breakthroughs in Personalized Care With Immunotherapy and Targeted Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Hope For Stomach Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Astellas, AstraZeneca, BeOne Medicines, Bristol Myers Squibb, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

The addition of perioperative durvalumab in gastric and gastroesophageal junction cancer improved event-free survival, according to findings from the MATTERHORN study. “This trial will be an important milestone,” said Yelena Y. Janjigian, MD, chief of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center in New York City, who presented the findings at the 2025 American Society of Clinical Oncology Annual Meeting. She spoke with Robert A. Figlin, MD, the interim director of Cedars-Sinai Cancer in Los Angeles and Steven Spielberg Family Chair in Hematology-Oncology, about the significance of the data. “We demonstrated improvement in event-free survival, and this is the first regimen in the perioperative setting to do so,” Dr. Janjigian noted. She also shared next steps for the research and broader questions that the data raise across oncology. Dr. Janjigian reported various financial relationships. Dr. Figlin reported various financial relationships.

Send us a textLearn all about an approach to gastric cancer for the internist! Episode written by Dr. Gurjit Mander (Internal Medicine)Reviewed by by Dr. Arjun Kundra (Gastroenterology) and Dr. Genevieve Chick (General Internal Medicine)Infographic by Dr. Gurjit ManderDo you ever feel like you can't get ahead of charting? Freed AI has an AI driven scribe for you! You can try Freed for free right now by going to getfreed.ai. Listeners can use the INTERN50 code for $50 off their first month!Support the show

JCO Editorial Fellow Dr. Peter Li and JCO Associate Editor Dr. Andrew Ko discuss the ASCO 25 Simultaneous Publication paper "Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III Randomized LEAP-015 Study." Transcript The guest on this podcast episode has no disclosures to declare. Dr. Peter Li: Hello, everyone, and welcome to our 2025 ASCO Annual Meeting Series where we cover some of the top JCO papers published simultaneously with their abstract presentation at this year's meeting. I'm your host, Dr. Peter Li, JCO Editorial Fellow, and I'm joined by Dr. Andrew Ko, JCO Associate Editor, to discuss the Journal of Clinical Oncology article and abstract presentation "Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III Randomized LEAP-015 Study." Now, let's start off with the relevance of this article. Andrew, can you please explain this to our listeners? Dr. Andrew Ko: Sure. Thanks, Peter. So, this was a very large international study evaluating the combination of lenvatinib and pembrolizumab. And just for context, that combination has been approved for use in other solid tumor types. It's FDA approved for renal cell carcinoma, for example, and endometrial carcinoma. But this study was looking specifically at this combination together with a chemotherapy backbone - so either FOLFOX or CAPOX - and comparing that to what at the time was a standard of care, which was just standard chemotherapy by itself. So, this very large study was intending to look at this particular novel combination. And we can get into some of the nuances of this study because the way that the experimental, the combination arm, was designed was perhaps a little bit more on the unusual side and led to maybe some imbalance in terms of how we think about the respective arms. Dr. Peter Li: Okay. We can definitely talk more about that as we go on. So, what are some of the key results of this study, and how do you think this will impact practice in the future? Dr. Andrew Ko: That's a good question. Technically, it was not a positive study. Well, it was positive in the sense that the co-primary endpoints - which included both progression-free survival and overall survival - so, progression-free survival, it did technically meet its endpoint, both in terms of the overall population and the preplanned subgroup analysis of patients who had a PD-L1 CPS of greater than or equal to 1. So, there was a PFS benefit with the experimental combination - the lenvatinib, pembrolizumab, plus chemotherapy - compared to chemotherapy alone. I will say the benefit was on the more modest side. So, if you even look at the medians, it was not a marked difference. If you look at the hazard ratios, they did meet statistical significance. On the other hand, this did not translate into a benefit for overall survival. So, when you ask, "Well, is this going to inform practice?" I'd have to say no. It highlights, I think, that JCO does want to publish articles that aren't necessarily going to be practice-changing, but that I think offer a lot of insights into trial design and important aspects of investigating novel treatments, even if they don't end up moving the needle in routine clinical practice. Dr. Peter Li: I totally agree with you. I mean, it was significant in terms of progression-free survival, but again, not clinically significant. And then overall survival, the interventional arm actually appeared to do slightly worse overall. Can you make some comments on the strengths and the weaknesses of this study, and where do you see us going from here? Dr. Andrew Ko: So, I think a couple of things worth highlighting in this study, very well designed, more than 800 patients in total. So, first of all, as I mentioned at the beginning, the combination was a little bit unique in terms of patients enrolled to the experimental arm got the combination of lenvatinib, pembrolizumab, together with chemotherapy for a very finite duration. So, that period of chemotherapy they received was only three months. And per protocol, patients then just segued to, quote unquote “maintenance treatment” with just the lenvatinib and pembrolizumab combination. Whereas patients on the control arm, meaning chemotherapy alone, would continue chemotherapy basically in perpetuity until their disease progressed or intolerable toxicity. So, there really was an imbalance in terms of, if you think that chemotherapy or continuing chemotherapy beyond that initial three-month period of time may be significant, that could have had some impact on the robustness or the efficacy of the experimental arm. There were some other aspects in terms of perhaps some differences in the rates of post-progression treatment, in other words, patients going on to receive second-line treatment. I think the other very relevant aspect, Peter, in this study was that the control arm - and no fault of the investigators - but the control arm at the time the study was ongoing just consisted of chemotherapy, FOLFOX CAPOX, by itself, without an immune checkpoint inhibitor, right? And we clearly know, based on results of several large phase III studies, and it's now in standard clinical practice, that we routinely use chemotherapy plus an immune checkpoint inhibitor. Certainly for patients with CPS PD-1/PD-L1 scores that are, well, you could argue greater than 1, or perhaps greater than 5 or 10. But the point being that the control arm of the study probably doesn't reflect what is currently used in clinical practice. And that's just always a challenge in clinical trial design, right? That when a study is designed and when it rolls out, you're always at risk in a rapidly changing and moving field that the standard of care may evolve during the lifetime of that particular trial, which is what I think you see in LEAP-015. Dr. Peter Li: Totally understand. And the survival we see from this study is also roughly similar to the combination of immuno-chemotherapy that is the standard of care today, which is, the authors mentioned, 12 to 14 months. Thank you so much, Andrew, for your input and for speaking about the JCO article "Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III Randomized LEAP-015 Study." Join us again for the latest simultaneous publications from the 2025 ASCO Annual Meeting. Please take a moment to rate, review, and subscribe to all ASCO podcast shows at asco.org/podcasts. Until then, enjoy the rest of ASCO 2025. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

- Overview of Gastric Cancer, Including Diagnosis & Staging - Current Standard of Care, Including Chemotherapy - New Treatment Approaches & the Role of Targeted Treatment & Immunotherapy - Precision Medicine: Predicting Response to Treatment - The Role of Clinical Trials: How Research Contributes to Treatment Options - Controlling Treatment Side Effects, Symptoms, Discomfort, & Pain - The Importance of Communicating with Your Health Care Team About Quality-of-Life Concerns - Nutrition & Hydration Concerns & Tips - Guidelines to Prepare for Telehealth/Telemedicine Appointments Including, Technology, Prepared List of Questions, Follow-Up Appointments & Discussion of OpenNotes - Questions for Our Panel of Experts

Join us on SurgOnc Today as we delve into the complexities of surgical treatment for stage IV gastric cancer. This episode explores the latest strategies and considerations for patients with advance disease including patients with positive peritoneal cytology, peritoneal carcinomatosis, liver metastasis and para-aortic nodal disease. We discuss the evolving role of surgery in improving outcomes for these patients. In this episode of SurgOnc today, Ahmed Dehal and Erin Ward from the SSO GI disease site working group Interview Dr. Lordick From University of Leipzig and Dr. Badgwell From MD Anderson Cancer Centre to discuss the topic.

Matters Microbial #83: Helicobacter — Passing the Acid Test March 19, 2025 Today, Dr. Karen Ottemann, Professor and Chair of the Department of Microbiology and Environmental Toxicology at the University of California Santa Cruz joins the #QualityQuorum to discuss the fascinating strategies of Helicobacter pylori, which can cause gastric ulcers and even stomach cancer in people. Host: Mark O. Martin Guest: Karen Ottemann Subscribe: Apple Podcasts, Spotify Become a patron of Matters Microbial! Links for this episode An overview of Helicobacter pylori and its relationship to gastric ulcers and gastric cancer. A video on the relationship between Helicobacteri pylori and gastric diseases. The story of how Helicobacter pylori was finally demonstrated to be responsible for gastric ulcers and gastric cancer. The prevalence of Helicobacter pylori world wide. When Helicobacter pylori does not cause disease:  a possible theory. The mechanism by which Helicobacter pylori causes gastric ulcers. The mechanism by which Helicobacter pylori causes gastric cancer. An overview of gastric cancer. An overview of inflammation and cancer. One of the articles from Dr. Ottemann's research group discussed in this episode:  “Bacterial flagella hijack type IV pili proteins to control motility.” Another of the articles from Dr. Ottemann's research group discussed in this episode:  “Helicobacter pylori cheV1 mutants recover semisolid agar migration due to loss of a previously uncharacterized Type IV filament membrane alignment complex homolog.” Dr. Ottemann's faculty website. Dr. Ottemann's research website. Intro music is by Reber Clark Send your questions and comments to mattersmicrobial@gmail.com

Editor's Summary by Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief, and Linda Brubaker, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for articles published from February 22-28, 2025.

In this episode of SurgOnc Today®, Steve Kwon, MD, and Mike Mavros, MD, are joined by Joo Ha Hwang, MD, and Yanghee Woo, MD, for a discussion of managing patients at high-risk of gastric cancer development at the population-level and at the patient-level. The panel will also discuss nonoperative and operative strategies in managing precancerous gastric lesions and early gastric cancers.

CME credits: 1.25 Valid until: 30-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/first-line-advanced-gastric-cancer-best-practices-for-biomarker-directed-treatment-approachesa-case-study/29848/ The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines are regularly updated as new therapies are approved or as drugs received expanded indications. Moreover, data are constantly evolving regarding the role of biomarkers and treatment choice. This activity has been designed to provide an overview of the NCCN guidelines for gastric, colorectal, and hepatocellular cancers and the optimal application of these recommendations to clinical practice.

CME credits: 1.25 Valid until: 30-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/first-line-advanced-gastric-cancer-best-practices-for-biomarker-directed-treatment-approachesa-case-study/29848/ The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines are regularly updated as new therapies are approved or as drugs received expanded indications. Moreover, data are constantly evolving regarding the role of biomarkers and treatment choice. This activity has been designed to provide an overview of the NCCN guidelines for gastric, colorectal, and hepatocellular cancers and the optimal application of these recommendations to clinical practice.

Dr Christopher Lieu shares his perspectives on the evolving therapeutic landscape for patients with colorectal and gastroesophageal cancers, moderated by Dr Stephen "Fred" Divers. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/AON24).

Send us a textStomach cancer, often referred to as gastric cancer, is a sneaky cancer.  Its symptoms can be easily mistaken for more benign conditions like indigestion or acid reflux, making early detection a challenge. In our latest podcast episode, we delve into this complex disease with the help of two esteemed experts: gastroenterologist Dr. Walid Chaloub, and Dr. Ritu Mukherji, a medical oncologist from MedStar Georgetown Cancer Institute in D.C. Host Debra Schindler explores the biology of stomach cancer with her physician guests to understand how mutations in the DNA of stomach cells can lead to uncontrolled growth and tumor formation. This formidable disease often goes unnoticed until it has advanced significantly, highlighting the critical need for awareness and early detection. Dr. Mukherji shares the various risk factors associated with stomach cancer, including smoking, diet, and certain bacterial infections like H. Pylori. She emphasizes the importance of molecular testing in diagnosing and treating this disease, as it can reveal specific mutations that may be targeted with personalized therapies. The episode also explores the different diagnostic tools available, such as endoscopy and CT scans, and the role of tumor markers in assessing the presence of cancer. While these tools are invaluable, Dr. Mukherji stresses that they are not foolproof, underscoring the importance of comprehensive testing and expert analysis. One of the most enlightening parts of the discussion is the potential for treatment and even cure. While surgery is a common approach, not all patients are candidates. The podcast highlights the evolving role of chemotherapy, immunotherapy, and targeted therapies, offering hope to those battling this disease. Listeners will gain a deeper understanding of the symptoms to watch for, the importance of genetic predispositions, and the latest advancements in treatment. This episode is a must-listen for anyone interested in learning more about stomach cancer, whether for personal knowledge or to support a loved one. Tune in to this informative episode to arm yourself with the knowledge needed to recognize the signs of stomach cancer early and explore the treatment options available. Your Health, or that of someone you care about, could depend on it.---For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

Speaking of SurgOnc has a new home! New episodes can now be found under the Society of Surgical Oncology's podcast, SurgOnc Today, available on all major podcast platforms. Subscribe today to receive updates on new episode releases.  In this new episode of Speaking of SurgOnc, Dr. Rick Greene discusses with Dr. Michael Bouvet and Dr. Kristin Cox the applicability of M5A-IR800 to target human gastric cancer, as reported in their article, "Targeting Patient-Derived Orthotopic Gastric Cancers with a Fluorescent Humanized Anti-CEA Antibody."

Speaking of SurgOnc has a new home! New episodes can now be found under the Society of Surgical Oncology's podcast, SurgOnc Today, available on all major podcast platforms. Subscribe today to receive updates on new episode releases.  In this new episode of Speaking of SurgOnc, Dr. Rick Greene discusses with Dr. Michael Bouvet and Dr. Kristin Cox the applicability of M5A-IR800 to target human gastric cancer, as reported in their article, "Targeting Patient-Derived Orthotopic Gastric Cancers with a Fluorescent Humanized Anti-CEA Antibody."

Dr Tanios Bekaii-Saab from Mayo Clinic in Phoenix, Arizona, and Dr Philip A Philip from the Henry Ford Cancer Institute in Detroit, Michigan, discuss recent research presentations on the treatment of gastrointestinal cancers, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/PostESMO24/GI).

Did you know that a bacteria found in the gut of nearly half of the population is a contributor to peptic ulcers, gastric cancers and various other conditions? Is there anything we can DO about this highly transmissable bacteria?  Find out on this episode of Science Matters w/ Reed Davis and Dr. Aron Gonshor. Learn more about Functional Diagnostic Nutrition at fdntraining.com/resources. 

Editor's Summary by Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief of JAMA, and Preeti Malani, MD, MSJ, Deputy Editor of JAMA, the Journal of the American Medical Association, for articles published from September 28-October 4, 2024.

Gastric cancer is a leading cause of cancer death globally. Chronic H pylori infection is the primary cause of gastric cancer, responsible for at least 80% of the new cases. Constanza Camargo, PhD, of the National Cancer Institute joins JAMA Associate Editor John M. Inadomi, MD, to discuss co-testing with FIT and H pylori stool antigen to help prevent gastric cancer. Related Content: Fecal Immunochemical Test and Helicobacter pylori Stool Antigen Co-Testing Screening for Helicobacter pylori to Prevent Gastric Cancer

Pink Sheet reporters and editors discuss Pfizer's abrupt decision to withdraw Oxbryta (:32), the US FDA's Oncologic Drugs Advisory Committee bringing sponsors of approved products back to discuss labeling changes while competitors are pending (10:46), and the new CEO of a generic industry trade association (27:34). More On These Topics From The Pink Sheet Pfizer Withdraws Oxbryta, But Overall Market Impact May Be Limited: https://pink.citeline.com/PS155302/Pfizer-Withdraws-Oxbryta-But-Overall-Market-Impact-May-Be-Limited EMA Discusses Fatal Events That Prompted Pfizer To Pull Oxbryta From Global Markets: https://pink.citeline.com/PS155296/EMA-Discusses-Fatal-Events-That-Prompted-Pfizer-To-Pull-Oxbryta-From-Global-Markets New US FDA Adcomm Trend: Approved Cancer Meds Get Another Look When Competitors Coming: https://pink.citeline.com/PS155285/New-US-FDA-Adcomm-Trend--Approved-Cancer-Meds-Get-Another-Look-When-Competitors-Coming All Comers No More? US FDA AdComm Supports PD-L1 Threshold In Esophageal, Gastric Cancer: https://pink.citeline.com/PS155300/All-Comers-No-More-US-FDA-AdComm-Supports-PDL1-Threshold-In-Esophageal-Gastric-Cancer Pazdur Calls For 'Kumbaya' To Standardize ImmunoOncology Biomarkers: https://pink.citeline.com/PS155298/Pazdur-Calls-For-Kumbaya-To-Standardize-ImmunoOncology-Biomarkers New AAM CEO Looking To ‘Force Multiply' For US Generics Industry: https://pink.citeline.com/PS155294/New-AAM-CEO-Looking-To-Force-Multiply-For-US-Generics-Industry

Elizabeth Smyth, MD, FRCP - When They Need More Than Trastuzumab: Deciding on What's Next for Patients With HER2+ Gastric Cancer

Elizabeth Smyth, MD, FRCP - When They Need More Than Trastuzumab: Deciding on What's Next for Patients With HER2+ Gastric Cancer

Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.

Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.

Joe Ferra, CEO of Elevation Oncology, highlights the unmet needs in gastric cancer and the potential of targeting Claudins, proteins involved in cell adhesion. The current competitive landscape of antibody drug conjugates (ADCs) confirms the promise of a targeted therapy that delivers a cytotoxic drug directly to cancer cells. Targeting Claudin 18.2 with an ADC approach offers an opportunity to treat a broader range of tumors expressing a lower level of Claudin 18.2 than those currently treated by CAR-T therapy. This approach is being investigated as a single-agent drug with promise for use in combination for gastric cancer, pancreatic cancer and esophageal cancer. Joe explains, "As you likely know, in the continuum of cancer drugs, you have chemotherapy on one end that indiscriminately kills everything it touches. On the other end, you have uber-targeted therapies looking at specific drivers of what's driving that specific tumor. In our case at Elevation Oncology, we're focused on what we like to call selected targeted oncology drugs so that we are using the unique characteristics of the tumor to target and meet in a targeted way attempt to kill the tumor for a better outcome for the patient." "Gastric cancer in and of itself was an area where Claudin 18.2 is known to be highly expressed, but for gastric cancer, to your point, there's a huge unmet need. For most patients, once they're in second line or third line, the opportunity for drugs that are available to them today is, unfortunately for all of us, very dismal. We think there's a significant opportunity to utilize a Claudin 18.2 antibiotic drug conjugate for overall better outcomes for patients living with gastric cancer." "We quickly saw an ADC approach as an opportunity to treat a broader range of Claudin 18.2 expression. Now, as I'm sure you're aware, in any target in any tumor, there's always a range of expression for Claudin 18.2. In gastric cancer, it's known that as much as 80% of gastric cancer expressed Claudin 18.2 at some level. With that expression, we think an ADC approach will be able to treat a broader range of expression." #ElevationOncology #ADC #AntibodyDrugConjugate #SolidTumors #Claudin182 #Claudins #Cancer ElevationOncology.com Download the transcript here 

Joe Ferra, CEO of Elevation Oncology, highlights the unmet needs in gastric cancer and the potential of targeting Claudins, proteins involved in cell adhesion. The current competitive landscape of antibody drug conjugates (ADCs) confirms the promise of a targeted therapy that delivers a cytotoxic drug directly to cancer cells. Targeting Claudin 18.2 with an ADC approach offers an opportunity to treat a broader range of tumors expressing a lower level of Claudin 18.2 than those currently treated by CAR-T therapy. This approach is being investigated as a single-agent drug with promise for use in combination for gastric cancer, pancreatic cancer and esophageal cancer. Joe explains, "As you likely know, in the continuum of cancer drugs, you have chemotherapy on one end that indiscriminately kills everything it touches. On the other end, you have uber-targeted therapies looking at specific drivers of what's driving that specific tumor. In our case at Elevation Oncology, we're focused on what we like to call selected targeted oncology drugs so that we are using the unique characteristics of the tumor to target and meet in a targeted way attempt to kill the tumor for a better outcome for the patient." "Gastric cancer in and of itself was an area where Claudin 18.2 is known to be highly expressed, but for gastric cancer, to your point, there's a huge unmet need. For most patients, once they're in second line or third line, the opportunity for drugs that are available to them today is, unfortunately for all of us, very dismal. We think there's a significant opportunity to utilize a Claudin 18.2 antibiotic drug conjugate for overall better outcomes for patients living with gastric cancer." "We quickly saw an ADC approach as an opportunity to treat a broader range of Claudin 18.2 expression. Now, as I'm sure you're aware, in any target in any tumor, there's always a range of expression for Claudin 18.2. In gastric cancer, it's known that as much as 80% of gastric cancer expressed Claudin 18.2 at some level. With that expression, we think an ADC approach will be able to treat a broader range of expression." #ElevationOncology #ADC #AntibodyDrugConjugate #SolidTumors #Claudin182 #Claudins #Cancer ElevationOncology.com Listen to the podcast here 

In this episode of "Cancer Actually F**king Sucks", we sit down with Danny, an active duty Special Agent in the U.S. Air Force and a gastric cancer survivor. Danny takes listeners on a profound journey from diagnosis to triumph, sharing how his military training prepared him for his battle against cancer. Throughout the conversation, Danny sheds light on the pivotal role of the Hunter Seven Foundation, a nonprofit aiding active duty personnel and veterans in linking their illnesses to toxic exposures during deployment. From moments of challenge to unexpected sources of hope, Danny's story epitomizes resilience in the face of adversity, the importance of family, and the power of community. Tune in for an inspiring discussion around navigating cancer as a young adult and taking page out of Ted Lasso's book by believing - believing in yourself and that you'll make it through. We hope you enjoy! Find Danny at @thrift_shop_actual on Instagram, and learn more about the HunterSeven Foundation at @huntersevenfounation, as well. Don't forget to rate and review the podcast on Spotify and Apple Podcasts, and follow us on Instagram at @canceractuallysuckspod for more inspiring content! --- Send in a voice message: https://podcasters.spotify.com/pod/show/cancer-actually-sucks/message

Join the Behind the Knife Surgical Oncology Team as we discuss the presentation, work-up, and management of gastric cancer. Hosts: - Timothy Vreeland, MD, FACS (@vreelant) is an Assistant Professor of Surgery at the Uniformed Services University of the Health Sciences and Surgical Oncologist at Brooke Army Medical Center - Connor Chick, MD (@connor_chick) is a Surgical Oncology fellow at Ohio State University. - Lexy (Alexandra) Adams, MD, MPH (@lexyadams16) is a PGY-6 General Surgery resident at Brooke Army Medical Center - Beth (Elizabeth) Carpenter, MD (@elizcarpenter16) is a PGY-5 General Surgery resident at Brooke Army Medical Center Learning Objectives: In this episode, we review the basics of gastric cancer, including presentation, work-up, staging, and treatment modalities as well as high yield topics including the Siewert classification system. We also briefly discuss trials establishing peri-operative chemotherapy regimens for gastric cancer and the controversy of D1 vs. D2 lymphadenectomy. Links to Papers Referenced in this Episode Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. NEJM 2006 Jul;355(1):11-20. https://www.nejm.org/doi/full/10.1056/NEJMoa055531 Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesphageal junction adenocarcinoma (FLOT4): a randomized, phase2/3 trial Lancet 2019 May;393(10184):1948-1957. https://pubmed.ncbi.nlm.nih.gov/30982686/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

In this episode, we speak with Joo Ha Hwang, MD, PhD who is a Professor of Medicine in Gastroenterology & Hepatology at Stanford University. We'll discuss why gastric cancer often goes undiagnosed until later stages, the lack of specific guidelines for screening and treatment in Asian populations, the prevalence and primary risk factors for gastric cancer, particularly H. pylori infection, with a focus on East Asians' elevated risk. Join us as Dr. Hwang shares insights on improving detection and prevention rates in this patient population. Read Transcript CME Information: https://stanford.cloud-cme.com/medcastepisode84 Claim CE and MOC: https://stanford.cloud-cme.com/Form.aspx?FormID=1910

Prof Eric Van Cutsem from University Hospitals Leuven in Leuven, Belgium, discusses recent updates on available and novel treatment strategies for gastroesophageal cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/YiR2023/Gastroesophageal2).

This episode is hosted by Josie Baker, MS, LGC, and features Jeremy Davis, MD, a National Cancer Institute (NIH) surgical oncologist.Together, they discuss Dr. Davis' recent article published in the Journal of Medical Genetics  titled “Decision-making and regret in patients with germline CDH1 variants undergoing prophylactic total gastrectomy.”This podcast was released during  Patient Experience Week.   Read our blog post to learn more about this podcast HERE

Dr Kanwal Raghav from The University of Texas MD Anderson Cancer Center in Houston discusses the role of HER2-directed therapy in the treatment of gastrointestinal tumors beyond gastroesophageal cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayHER2PanTumor23/2GI).

Dr Yelena Y Janjigian from Memorial Sloan Kettering Cancer Center in New York and Dr Zev Wainberg from UCLA Jonsson Comprehensive Cancer Center in Los Angeles discuss the management of gastroesophageal cancers and review emerging data sets in the field, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/YiR2023/Gastroesophageal).